![](https://www.webhealthnetwork.com/img/webhealth-logo.png)
Hyperlipoproteinemia Type I - 48 Studies Found
Terminated |
: Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies : Hyperlipoproteinemia Type I : 2011-09-28 |
Terminated |
: Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome. : Familial Chylomicronemia Syndrome (FCS) (HLP Type I) : 2012-04-27 : Drug: LCQ908 |
Recruiting |
: Orlistat for the Treatment of Type I Hyperlipoproteinemia :
: 2016-05-02 : Drug: Orlistat Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for wei |
Completed |
: The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome : Familial Chylomicronemia Syndrome : 2014-08-05 :
|
Completed |
: A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome : Familial Chylomicronemia Syndrome (FCS) : 2011-12-21 :
|
Recruiting |
: The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome :
|
Recruiting |
: Alipogene Tiparvovec for the Treatment of LPLD Patients : LPL Deficiency : 2016-05-10 :
|
Not yet recruiting |
: Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment : Lipoprotein Lipase Deficiency : 2016-01-12 : Drug: Heparin Participants will be given IV heparin in order to release lipoprotein lipase from capillar |
Not yet recruiting |
: Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X] : Familial Lipoprotein Lipase Deficiency : 2010-04-22 :
|
Completed |
: Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects : Familial Lipoprotein Lipase Deficiency : 2009-04-30 :
|